New York, June 3, 2026, 04:20 EDT
Hemab Therapeutics Holdings (COAG) is set to open Wednesday pre-market at $27.47, up around 53% from its $18 IPO price. Investors now turn to the company’s management, who are scheduled to present at the Jefferies Global Healthcare Conference on Thursday. Shares finished Tuesday up 1.25% after a volatile first month since going public, according to market data.
Hemab is still a new Nasdaq biotech, so the focus has shifted away from the listing to whether it can keep its lead drug program on track for late-stage trials. The company is slated for a fireside chat at 9:20 a.m. ET on June 4 in New York at a healthcare conference that runs from June 2-4.
U.S. regular trading was still closed at the time. Nasdaq opens regular hours at 9:30 a.m. and shuts at 4:00 p.m. ET. System hours start at 4:00 a.m. Nasdaq’s list of 2026 holidays does not include June 3. The next full close is Juneteenth, June 19.
Hemab sold 19.26 million shares at $18 apiece in its larger-than-planned IPO in May, bringing in $346.7 million in gross proceeds. The company’s stock trades on the Nasdaq Global Select Market as COAG.
Hemab ended the quarter with $163.5 million in cash, cash equivalents and marketable securities as of March 31. That was before factoring in about $317.2 million in IPO net proceeds. The company said that total should cover its operating and capital needs into 2029, important for a clinical-stage drugmaker that still doesn’t have an approved product.
Hemab’s main drug, sutacimig, is a bispecific antibody, or a single drug that binds to two different targets. The company is developing sutacimig as a preventive therapy for Glanzmann thrombasthenia and Factor VII deficiency. Both are rare genetic bleeding disorders. Hemab plans to start a pivotal Phase 3 trial in Glanzmann thrombasthenia in the second half of 2026. Pivotal trials are typically needed for approval.
Hemab CEO Benny Sørensen said in May the focus is on getting sutacimig to pivotal trials and pushing ahead with HMB-002, the company’s Von Willebrand disease candidate. Data from the Factor VII deficiency and HMB-002 programs is expected by late 2026 or early 2027.
Wedbush’s David Nierengarten started coverage on Hemab Therapeutics with an Outperform and a $42 target, according to StreetInsider. Nierengarten said Hemab is a “high conviction opportunity within rare coagulation disorders.” Analysts have been quick to tie the stock’s moves to upcoming trial dates. Streetinsider
Competition is limited. Hemab said in its IPO filing there are no approved subcutaneous preventive treatments for Glanzmann thrombasthenia or Factor VII deficiency. Patients usually get treated after bleeds. Novo Nordisk’s NovoSeven RT is approved for Glanzmann thrombasthenia if platelets don’t work, but it’s used differently than what Hemab is targeting—a preventive, subcutaneous shot.
Medical need stays central to the stock pitch. Back in March, Hemab said the FDA gave Breakthrough Therapy Designation to sutacimig for Glanzmann thrombasthenia. That status is supposed to help development and review if early data show a drug might do better than current treatment. “The unmet need…is clear,” Suthesh Sivapalaratnam of Barts Health NHS Trust and Queen Mary University of London said at the time. Hemab
Risks are still big. Hemab has no approved drugs and has never booked product sales. The company said in its filing it hasn’t started pivotal trials for any candidate. Setbacks like trial delays, poor data or safety flags could pressure the shares and renew questions about funding.
Right now, the story breaks into two main signals: shares at $27.47 and no big clinical catalysts until the latter half of 2026. Thursday’s conference appearance isn’t a regulatory touchpoint. Still, with the company on the tape for just over a month since its IPO, even standard updates from management could draw extra attention.
